Glafenine

Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) [1][2][3][4].

Product Specifications

CAS Number

[3820-67-5]

Product Name Alternative

Glafenin

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; CFTR; COX; Endoplasmic Reticulum Oxidoreductase 1 (ERO1)

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Glafenine.html

Purity

98.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC(O)CO)C1=CC=CC=C1NC2=CC=NC3=CC(Cl)=CC=C23

Molecular Formula

C19H17ClN2O4

Molecular Weight

372.80

Precautions

H315, H319, H335

References & Citations

[1]Schöber W, et al. Impact of glafenine hydrochloride on human endothelial cells and human vascular smooth muscle cells: a substance reducing proliferation, migration and extracellular matrix synthesis. Cell Biol Int. 2003;27 (12) :987-96|[2]Carlile GW, et al. The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway. Sci Rep. 2022 Mar 17;12 (1) :4595|[3]Goldsmith JR, et al. Glafenine-induced intestinal injury in zebrafish is ameliorated by μ-opioid signaling via enhancement of Atf6-dependent cellular stress responses. Dis Model Mech. 2013 Jan;6 (1) :146-59.|[4]Chiu AM, et al. High Throughput Assay Identifies Glafenine as a Corrector for the Folding Defect in Corneal Dystrophy-Causing Mutants of SLC4A11. Invest Ophthalmol Vis Sci. 2015 Dec;56 (13) :7739-53.